Rapid Micro Biosystems | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 7.838 M

LB filings
2025.11.07 11:10
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 7.838 M, beating the estimate of USD 7.6 M.

EPS: As of FY2025 Q3, the actual value is USD -0.26, missing the estimate of USD -0.245.

EBIT: As of FY2025 Q3, the actual value is USD -11.33 M.

Financial Metrics by Segment

Segment Revenue

  • Total revenue for Q3 2025: $7.8 million, a 3% increase from $7.6 million in Q3 2024.
  • Product revenue for Q3 2025: $5.2 million, compared to $5.3 million in Q3 2024.
  • Service revenue for Q3 2025: $2.6 million, a 12% increase from $2.3 million in Q3 2024.
  • Recurring revenue for Q3 2025: $4.8 million, a 32% increase from $3.7 million in Q3 2024.

Gross Margin

  • Gross margin for Q3 2025: 9%, compared to 8% in Q3 2024.

Operating Expenses

  • Total operating expenses for Q3 2025: $12.1 million, a 5% decrease from $12.7 million in Q3 2024.
    • General and administrative expenses: $5.6 million, a 1% decrease from $5.7 million in Q3 2024.
    • Research and development expenses: $3.5 million, a 2% decrease from $3.6 million in Q3 2024.
    • Sales and marketing expenses: $2.9 million, a 14% decrease from $3.4 million in Q3 2024.

Net Loss

  • Net loss for Q3 2025: $11.5 million, compared to $11.3 million in Q3 2024.
  • Net loss per share for Q3 2025: $0.26, unchanged from Q3 2024.

Cash Flow and Investments

  • Cash, cash equivalents, short-term investments, and restricted cash as of September 30, 2025: $42 million.

Outlook / Guidance

  • The company raised its full-year 2025 total revenue guidance to at least $33.0 million, assuming at least 27 Growth Direct system placements.
  • The outlook includes a significant contribution from the record multi-system customer order received in October 2025.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.